With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape

Moderna, Inc.’s revenues from its COVID-19 vaccines have begun an anticipated decline, reflecting the broader trend in drugs and vaccines for SARS-CoV-2 as the pandemic begins to wind down, and it is forecasting a steep drop in coronavirus vaccine sales in 2023. But the messenger RNA-focused biotech’s fourth quarter and full year 2022 earnings also hint that the post-pandemic future that it has been building toward is taking shape as newer mRNA-based products inch closer to the market, particularly in infectious diseases like respiratory syncytial virus (RSV) and oncology.

Moderna announced its earnings on 23 February, reporting fourth quarter revenues of $5.1bn and full year revenues of $19.3bn, nearly all of which – $4.9bn and $18